Clinical Trial Update: Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lymphodepletion plus anti-PD-1 blockade to reduce relapse in acute myeloid leukemia patients ineligible for transplant; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Anti-PD-1 blockade (immune checkpoint inhibitor targeting PD-1)

Snippet

Sponsor: Northside Hospital, Inc. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2023-09-22